Duodenal infusion of feces for recurrent Clostridium difficile [1]

New England Journal of Medicine

Volumn 368, Issue 22, 2013, Pages 2143-2145

  Van Schooneveld, Trevor C ^a   Gross, Alan ^b   Kalil, Andre C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG EXPOSURE; FECAL MICROBIOTA THERAPY; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; CLOSTRIDIUM DIFFICILE; DIARRHEA; FECES; FEMALE; MALE; MICROBIOLOGY; NOTE; DRUG EFFECT; INFUSION; RISK BENEFIT ANALYSIS; THERAPY EFFECT; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; FECES; FEMALE; HUMANS; MALE; VANCOMYCIN;

EID: 84878364404     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1303919     Document Type: Letter

References (5)

1. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15.
2. Pereira TV, Horowitz RI, Ioannidis JPA. Empirical evaluation of very large treatment effects of medical interventions. JAMA 2012;308:1676-84.
3. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:1011-9.
4. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31.
5. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205.